Research Articles

Effectiveness of Shenshu Guanxin recipe granules (参术冠心方颗粒) for improving exercise tolerance in patients with stable angina pectoris: a randomized, double-blind, placebo-controlled trial

  • Xiao JIN ,
  • Bingxin WU ,
  • Huanlin WU ,
  • Danping XU
Expand
  • 1 Department of Traditional Chinese Medicine, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
    2 Department of Cardiology, Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China
    3 Department of Cardiology, Dongzhimen Hosipital, Beijing 100029, China
    4 Department of Traditional Chinese Medicine, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China

Received date: 2022-02-12

  Accepted date: 2022-05-13

  Online published: 2023-10-08

Supported by

Exploring the Mechanism of Shenshu Guanxin Formula in Intervention of Myocardial Ischemia Based on MiR-24 Mediated Bim/Caspase Apoptosis Signal Pathway(A2021349);Exploring the Intervention of Shenshu Guanxin Formula on Myocardial Ischemia Based on MiR-24 Mediated Bim/Caspase Apoptosis Signal Pathway Mechanism Research(21621062);to Study the Mechanism of Hesperidin in Improving Heart Failure Based on Myocardial Inflammation Mediated by MtDNA-sGAS-STING Signaling Pathway(JCYJ20220530144212026)

Abstract

OBJECTIVE: To assess the effectivess of Shenshu Guanxin recipe granules (参术冠心方颗粒, SGR) in improving exercise tolerance and the quality of life in patients with Stable Angina Pectoris (SAP).
METHODS: A total of 189 patients were consecutively enrolled between December 2012 and December 2014. The included patients were randomly assigned to SGR and placebo groups. The primary endpoints included mainly the results of treadmill exercise test and Seattle Angina Questionnaire (SAQ) during 12 weeks of treatment.
RESULTS: After 12 weeks of treatment, SGR extended the time of exercise-induced ST-segment depression of 0.1 MV, lowered the maximum ST-segment depression, and shortened the duration of ST-segment depression in patients with SAP in southern China. Besides, the study also proved that SGR could improve the quality of life and functional status of patients with SAP.
CONCLUSIONS: SGR showed a positive effect on exercise tolerance compared with the placebo besides optimal medical therapy. Also, the study proved that SGR could improve the SAQ score of the patients.

Cite this article

Xiao JIN , Bingxin WU , Huanlin WU , Danping XU . Effectiveness of Shenshu Guanxin recipe granules (参术冠心方颗粒) for improving exercise tolerance in patients with stable angina pectoris: a randomized, double-blind, placebo-controlled trial[J]. Journal of Traditional Chinese Medicine, 2023 , 43(6) : 1227 -1233 . DOI: 10.19852/j.cnki.jtcm.20231008.001

References

1. Collaborators GCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390: 1151-210.
2. Zhu KF, Wang YM, Zhu JZ, Zhou QY, Wang NF. National prevalence of coronary heart disease and its relationship with human development index: a systematic review. Eur J Prev Cardiol 2016; 23: 530-43.
3. Chen M, Li M, Ou L, et al. Effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris: Protocol for a systematic review. Medicine (Baltimore) 2018; 97: e11680.
4. Manolis AJ, Ambrosio G, Collins P, et al. Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. Eur J Intern Med 2019; 70: 60-7.
5. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of Cardiology/American heart association task force on clinical practice guidelines:an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients wth stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016; 134: e123-55.
6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J 2013; 34: 2949-3003.
7. Timmis A, Roobottom CA. National institute for health and care excellence updates the stable chest pain guideline with radical changes to the diagnostic paradigm. Heart 2017; 103: 982-86.
8. Lam TH, Liu LJ, Janus ED, Lau CP, Hedley AJ. Fibrinogen, angina and coronary heart disease in a Chinese population. Atherosclerosis 2000; 149: 443-9.
9. Luo J, Shang Q, Han M, Chen K, Xu H. Traditional Chinese Medicine injection for angina pectoris: an overview of systematic reviews. Am J Chin Med 2014; 4: 37-59.
10. Tang Y, Cai H, Zhan Z, et al. Herbal medicine (Zhishi Xiebai Guizhi decoction) for unstable angina: Protocol for a systematic review and Meta-analysis. Medicine (Baltimore) 2018; 97: e13965.
11. Zhang Z, Zhang F, Wang Y, et al. Traditional Chinese Medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial. Trials 2014; 15: 422-28.
12. Jo J, Leem J, Lee JM, Park KS. Herbal medicine (Hyeolbuchukeo-Tang or Xuefu Zhuyu decoction) for treating primary dysmenorrhoea: protocol for a systematic review of randomised controlled trials. BMJ Open 2017; 7: e015056.
13. Wang PQ, Li DD, Dong W, et al. Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials 2015; 16: 474-9.
14. Huang J, Tang X, Ye F, He J, Kong X. Clinical therapeutic effects of aspirin in combination with Fufang Danshen Diwan, a Traditional Chinese Medicine formula, on coronary heart disease: a systematic review and Meta-analysis. Cell Physiol Biochem 2016; 39: 1955-63.
15. Zhang Y, Xie Y, Liao X, Jia Q, Chai Y. A Chinese patent medicine salvia miltiorrhiza depside salts for infusion combined with conventional treatment for patients with angina pectoris: a systematic review and Meta-analysis of randomized controlled trials. Phytomedicine 2017; 25: 100-17.
16. Mao S, Xu DP, Dang XJ, Li W, Wu HL. Shenzhu Guanxin recipe granules for improving exercise tolerance in patients with stable angina (SERIES Trial): a protocol of multicenter, randomized, double-blind, placebo parallel controlled clinical trial. Chin J Integr Med 2019; 25: 96-102.
17. Xu DP, Wu HL, Lan TH, et al. Effect of Shenzhu Guanxin recipe on patients with angina pectoris after percutaneous coronary intervention: a prospective, randomized controlled trial. Chin J Integr Med 2015; 21: 408-16.
18. Xu DP, Zou DZ, Qiu HL, Wu HL. Traditional Chinese Medicine Shenzhu Guanxin granules mitigate cardiac dysfunction and promote myocardium angiogenesis in myocardial infarction rats by upregulating PECAM-1/CD31 and VEGF Expression. Evid Based Complement Alternat Med 2017;2017: 5261729.
19. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012; 10: 28-55.
20. Shkolnik E, Burneikaite G, Celutkiene J, et al. Efficacy of cardiac shock wave therapy in patients with stable angina: the design of randomized, triple blind, sham-procedure controlled study. Anatol J Cardiol 2018; 19: 100-9.
21. Shkolnik E, Burneikaite G, Jakutis G, et al. A randomized, triple-blind trial of cardiac shock-wave therapy on exercise tolerance and symptoms in patients with stable angina pectoris. Coron Artery Dis 2018; 29: 579-86.
22. Kaul P, Naylor CD, Armstrong PW, Mark DB, Theroux P, Dagenais GR. Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. Can J Cardiol 2009; 25: e225-31.
23. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American college of cardiology joint committee on clinical practice guidelines. Circulation 2023; 148: e9-119.
24. Zhao S, Tang Y, Cai H, et al. Treatment of Danhong injection combined with Naoxintong capsule in acute coronary syndrome patients undergoing PCI operation: study for a randomized controlled and double-blind trial. Evid Based Complement Alternat Med 2018; 2018: 8485472.
25. Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, Mejia Dolores JW, Rey Rodriguez DE, Loza Munárriz C. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev 2017; 2: Cd011747.
26. Liao W, Ma X, Li J, et al. A review of the mechanism of action of Dantonic(?) for the treatment of chronic stable angina. Biomed Pharmacother 2019; 109: 690-700.
27. Ren Y, Zhang M, Chen K, et al. Clinical and epidemiological investigation of TCM syndromes of patients with coronary heart disease in China. Evid Based Complement Alternat Med 2012; 2012: 714517.
28. Huang M, Wu H, Wu J, Chen Q, Zou D, Xu D. Prevention of platelet aggregation and arterial thrombosis using a modified Shenzhu Guanxin formula. J Int Med Res 2020; 48: 300-26.
29. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. Faseb j 2009; 23: 3361-7.
Outlines

/